Novo Nordisk has terminated its marketing deal with telehealth company Hims & Hers, citing unlawful mass compounding and deceptive marketing of its obesity treatment Wegovy. The partnership, formed to transition patients using compounded drugs during FDA-declared shortages to branded therapy, was ended following the expiration of the shortage designation in February. Novo emphasized patient safety concerns related to unregulated, illicit pharmaceutical ingredients distributed under the guise of personalization by Hims.